2025-04-02 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**0. Summary Statistics:**

LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period.  While showing some recent price decline,  the company boasts strong revenue and profitability, and a high expected return.  Further investigation is needed to understand the recent price dip.


**1. Performance Comparison:**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company.

* **LLY Cumulative Return:** 345.35%
* **VOO (S&P 500) Cumulative Return:** 89.83%
* **Return Difference:** 255.52%
* **Relative Divergence:** 66.1% (This indicates LLY's performance is significantly above the S&P 500, positioned at the 66.1 percentile of its historical range relative to the S&P 500)

The provided Alpha and Beta analysis showcases LLY's consistent outperformance (positive alpha) against the market (beta varies around 1).  Market capitalization has also grown considerably over the years.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 8.3% | -7.0% | 0.1 | 65.8 |
| 2016-2018  | 47.0% | 8.3% | 41.0% | -0.0 | 92.5 |
| 2017-2019  | 59.0% | 9.8% | 40.0% | 0.3 | 107.4 |
| 2018-2020  | 70.0% | 13.5% | 36.0% | 0.2 | 140.7 |
| 2019-2021  | 118.0% | 13.5% | 45.0% | 0.1 | 233.7 |
| 2020-2022  | 128.0% | 48.4% | 116.0% | 0.1 | 313.7 |
| 2021-2023  | 182.0% | 51.4% | 164.0% | 0.3 | 504.8 |
| 2022-2024  | 206.0% | 55.2% | 183.0% | 0.3 | 673.0 |
| 2023-2025  | 169.0% | 81.7% | 128.0% | 0.2 | 721.2 |


**2. Recent Price Movement:**

* **Closing Price:** $825.91
* **Last Market Price:** $803.06 (A decline of $22.85)
* **5-day Moving Average:** $829.84
* **20-day Moving Average:** $844.62
* **60-day Moving Average:** $831.42

The price is currently below all three moving averages, suggesting a bearish short-term trend. The recent price drop is notable and requires further investigation.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.44 (Medium Risk)
* **RSI:** 50.63 (Near neutral; neither overbought nor oversold)
* **PPO:** -0.32 (Negative; suggesting bearish momentum)
* **20-day Relative Divergence Change:** -0.4 (Short-term downtrend)
* **Expected Return (vs. S&P 500):** 108.3% over the long term (2+ years), indicating significant potential for outperformance.

The recent price drop (`change`: -2.77) reflects a bearish trend but is not extremely sharp.  Given the high expected return, this short-term dip could be a buying opportunity for long-term investors.

**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue       |
|------------|---------|---------------|
| 2024-10-30 | $1.08   | $11.44 B      |
| 2024-08-08 | $3.29   | $11.30 B      |
| 2024-04-30 | $2.49   | $8.77 B       |
| 2023-11-02 | -$0.06  | $9.50 B       |
| 2024-10-30 | -$0.06  | $9.50 B       | *(Duplicate entry, likely an error)*


Earnings are highly variable.  While there were significant positive EPS numbers in Q2 and Q3 of 2024, the latest reported quarter shows a lower EPS.  More data is needed to determine the cause of the fluctuation.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $13.53B    | 82.24%       |
| 2024-09-30 | $11.44B    | 81.02%       |
| 2024-06-30 | $11.30B    | 80.80%       |
| 2024-03-31 | $8.77B     | 80.91%       |
| 2023-12-31 | $9.35B     | 80.88%       |

Revenue shows a generally upward trend, and profit margins remain consistently high.


**Capital and Profitability:**

| Quarter | Equity     | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $14.19B    | 31.07%       |
| 2024-09-30 | $14.24B    | 6.81%        |
| 2024-06-30 | $13.56B    | 21.88%       |
| 2024-03-31 | $12.81B    | 17.51%       |
| 2023-12-31 | $10.77B    | 20.33%       |

Equity is generally increasing, but ROE fluctuates.  The drop in ROE in Q3 2024 warrants further investigation.


**6. Overall Analysis:**

LLY exhibits strong long-term performance significantly exceeding the S&P 500.  Financial statements reveal robust revenue and high profit margins. However, recent price action indicates a short-term bearish trend, and recent earnings show volatility.  The high expected return and generally positive financial indicators suggest that the recent price decline might present a buying opportunity for long-term investors with a high-risk tolerance.  Further investigation into the reasons for the recent price drop and earnings volatility is recommended before making any investment decisions.  Analyzing news articles, analyst reports, and future earnings announcements will provide a more complete picture.
